• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research

SARS-CoV-2 omicron: Light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients?
J Allergy Clin Immunol Pract. 2022 Jun 22:S2213-2198(22)00597-9. doi: 10.1016/j.jaip.2022.06.011. Online ahead of print.ABSTRACTCOVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were at increased risk of severe disease. In addition, patients with some forms of immun...
Source: Clinical Lung Cancer - June 25, 2022 Category: Cancer & Oncology Authors: Rohan Ameratunga Euphemia Leung See-Tarn Woon Lydia Chan Richard Steele Klaus Lehnert Hilary Longhurst Source Type: research

Pre-existing comorbidities shape the immune response associated with severe COVID-19
CONCLUSION: The combinatorial systematic analysis of COVID-19 patient immune signatures, comorbidities, and patient outcomes provides the mechanistic immunological underpinnings of comorbidity-driven patient risk and uncovered comorbidity-driven immune signatures.PMID:35716951 | DOI:10.1016/j.jaci.2022.05.019
Source: Clinical Lung Cancer - June 18, 2022 Category: Cancer & Oncology Authors: Stefanie Kreutmair Manuel Kauffmann Susanne Unger Florian Ingelfinger Nicol ás Gonzalo Núñez Chiara Alberti Donatella De Feo Sinduya Krishnarajah Ekaterina Friebel Can Ulutekin Sepideh Babaei Benjamin Gaborit Mirjam Lutz Nicole Puertas Jurado Nisar P M Source Type: research

SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes
CONCLUSIONThese results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes.FUNDINGMark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Ha...
Source: Clinical Lung Cancer - July 1, 2021 Category: Cancer & Oncology Authors: Yijia Li Alexis M Schneider Arnav Mehta Moshe Sade-Feldman Kyle R Kays Matteo Gentili Nicole C Charland Anna Lk Gonye Irena Gushterova Hargun K Khanna Thomas J LaSalle Kendall M Lavin-Parsons Brendan M Lilley Carl L Lodenstein Kasidet Manakongtreecheep Ju Source Type: research

Air pollution, racial disparities, and COVID-19 mortality
Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and resulted in more than 200,000 coronavirus disease 2019 (COVID-19) deaths. Emerging data suggest that elderly people as well as individuals with underlying health conditions are at a higher risk of hospitalization and death.1-3 Interestingly, the Centers for Disease Control and Prevention ’s list of risk factors for severe COVID-19 (Fig 1) largely overlap with the list of diseases that are known to be worsened by chronic exposure to air pollution, including diabetes, heart diseases, and chronic airwa...
Source: Journal of Allergy and Clinical Immunology - May 6, 2020 Category: Allergy & Immunology Authors: Eric B. Brandt, Andrew F. Beck, Tesfaye B. Mersha Tags: Editorial Source Type: research

New Tests Enter the Scene as COVID-19 Rages On
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions. Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test. In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab...
Source: MDDI - March 16, 2020 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news

Variation in DNA-Damage Responses to an Inhalational Carcinogen (1,3-Butadiene) in Relation to Strain-Specific Differences in Chromatin Accessibility and Gene Transcription Profiles in C57BL/6J and CAST/EiJ Mice
Conclusions: These results suggest that strain-specific changes in chromatin and transcription in response to chemical exposure lead to a “compensation” for underlying genetic-driven interindividual differences in the baseline chromatin and transcriptional state. This work represents an example of how chemical and environmental exposures can be evaluated to better understand gene-by-environment interactions, and it demonstrates the important role of chromatin response in transcriptomic changes and, potentially, in deleterious effects of exposure. https://doi.org/10.1289/EHP1937 Received: 21 March 2017 Revis...
Source: EHP Research - October 17, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research